Annals of pancreatic cancer

Keyphrases

Publications

volume 6, number 10, 2023

Kaiyi Mu, Juan Fu, Jessica Gai, Harshitha Ravichandran, Lei Zheng, Wei-Chih Sun
Genetic alterations in the neuronal development genes are associated with changes of the tumor immune microenvironment in pancreatic cancer. Annals of pancreatic cancer 6 (10) (2023)
Kaiyi Mu, Juan Fu, Jessica Gai, Harshitha Ravichandran, Lei Zheng, Wei-Chih Sun
Genetic alterations in the neuronal development genes are associated with changes of the tumor immune microenvironment in pancreatic cancer. Annals of pancreatic cancer 6 (10) (2023)
Kaiyi Mu, Juan Fu, Jessica Gai, Harshitha Ravichandran, Lei Zheng, Wei-Chih Sun
Genetic alterations in the neuronal development genes are associated with changes of the tumor immune microenvironment in pancreatic cancer. Annals of pancreatic cancer 6 (10) (2023)

volume 5, 2022

Xiang Chen, Yi-Chieh Nancy Du
" RHAMM knockout" mice express a truncated RHAMM protein that promotes pancreatic cancer progression with dysfunctional p53. Annals of pancreatic cancer 5 (2022)
Xiang Chen, Yi-Chieh Nancy Du
" RHAMM knockout" mice express a truncated RHAMM protein that promotes pancreatic cancer progression with dysfunctional p53. Annals of pancreatic cancer 5 (2022)

volume 4, 2021

Muhammad A Rauf, Ioannis A Ziogas, Julia M Sealock, Lea K Davis, Manhal J Izzy, Sophoclis P Alexopoulos, Lea K Matsuoka
Pancreatic adenocarcinoma in liver transplant recipients: a case series. Annals of pancreatic cancer 4 (2021)
Matthew Williams, Umut Özbek, Jung-Yi Lin, Celina Ang
A single-institutional analysis of racial disparities in clinicopathologic characteristics, treatment selections, and outcomes in advanced-stage pancreatic cancer patients. Annals of pancreatic cancer 4 (2021)

volume 3, 2020

Arnav Mehta, William L Hwang, Colin Weekes
The present and future of systemic and microenvironment-targeted therapy for pancreatic adenocarcinoma. Annals of pancreatic cancer 3 (2020)
Alejandro Recio-Boiles, Jessica Vondrak, Summana Veeravelli, James J Mancuso, Kathylynn Saboda, Denise J Roe, Irbaz Bin Riaz, Aaron J Scott, Emad Elquza, Ali McBride, Hani M Babiker
Analyzing outcomes of neoadjuvant and adjuvant treatment for borderline-resectable pancreatic adenocarcinoma in the perioperative period at an academic institution. Annals of pancreatic cancer 3 (2020)
Mengni He, MacKenzie Henderson, Stephen Muth, Adrian Murphy, Lei Zheng
Preclinical mouse models for immunotherapeutic and non-immunotherapeutic drug development for pancreatic ductal adenocarcinoma. Annals of pancreatic cancer 3 (2020)
Joy Liau, Srinivasan Vedantham, Hani M Babiker, Travis McGlothin, Diego R Martin
Quantitative metric for assessment of pancreatic ductal adenocarcinoma treatment response in T1-weighted gadolinium-enhanced magnetic resonance imaging. Annals of pancreatic cancer 3 (2020)
Reecha Suri, Jacquelyn W Zimmerman, Richard A Burkhart
Modeling human pancreatic ductal adenocarcinoma for translational research: current options, challenges, and prospective directions. Annals of pancreatic cancer 3 (2020)
Talia Golan, Jonathan R Brody
Targeting homologous recombination addicted tumors: challenges and opportunities. Annals of pancreatic cancer 3 (2020)

volume 2, 2019

Imani Bijou, Jin Wang
Evolving trends in pancreatic cancer therapeutic development. Annals of pancreatic cancer 2 (2019)
Alejandro Recio-Boiles, Aparna Nallagangula, Summana Veeravelli, Jessica Vondrak, Kathylynn Saboda, Denise Roe, Emad Elquza, Ali McBride, Hani M Babiker
Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios inversely correlate to clinical and pathologic stage in patients with resectable pancreatic ductal adenocarcinoma. Annals of pancreatic cancer 2 (2019)
Yi Xu, Jun Liu, Michael Nipper, Pei Wang
Ductal vs. acinar? Recent insights into identifying cell lineage of pancreatic ductal adenocarcinoma. Annals of pancreatic cancer 2 (2019)
Jessica L Buicko, Brendan M Finnerty, Tiantian Zhang, Bu Jung Kim, Thomas J Fahey, Yi-Chieh Nancy Du
Insights into the biology and treatment strategies of pancreatic neuroendocrine tumors. Annals of pancreatic cancer 2 (2019)
Patrick W Underwood, Michael H Gerber, Steven J Hughes
Pitfalls of minimally invasive pancreatoduodenectomy. Annals of pancreatic cancer 2 (2019)
Noah S Rozich, Caitlin E Jones, Katherine T Morris
Malnutrition, frailty, and sarcopenia in pancreatic cancer patients: assessments and interventions for the pancreatic surgeon. Annals of pancreatic cancer 2 (2019)

volume 1, number 5, 2018

Efrat Dotan
Can computational modeling help in personalizing the care of patients with pancreatic ductal adenocarcinoma? Annals of pancreatic cancer 1 (5) (2018)

volume 1, number 8, 2018

Adam R Wolfe, Terence M Williams
Altering the response to radiation: radiosensitizers and targeted therapies in pancreatic ductal adenocarcinoma: preclinical and emerging clinical evidence. Annals of pancreatic cancer 1 (8) (2018)

volume 1, 2018

Nikhil Yegya-Raman, Mihir M Shah, Miral S Grandhi, Elizabeth Poplin, David A August, Timothy J Kennedy, Usha Malhotra, Kristen R Spencer, Darren R Carpizo, Salma K Jabbour
Adjuvant therapeutic strategies for resectable pancreatic adenocarcinoma. Annals of pancreatic cancer 1 (2018)
Gregory B Lesinski
Stressing for sugar: a new role of serotonin for glycolysis in pancreatic cancer cells. Annals of pancreatic cancer 1 (2018)
Amar B Deshwar, Elizabeth Sugar, Deirdre Torto, Ana De Jesus-Acosta, Matthew J Weiss, Christopher L Wolfgang, Dung Le, Jin He, Richard Burkhart, Lei Zheng, Daniel Laheru, Mark Yarchoan
Diagnostic intervals and pancreatic ductal adenocarcinoma (PDAC) resectability: a single-center retrospective analysis. Annals of pancreatic cancer 1 (2018)
Lei Zheng
Immune defects in pancreatic cancer. Annals of pancreatic cancer 1 (2018)
Sweet Ping Ng, Eugene J Koay
Current and emerging radiotherapy strategies for pancreatic adenocarcinoma: stereotactic, intensity modulated and particle radiotherapy. Annals of pancreatic cancer 1 (2018)